information

Whoever comes in this website may find a hint

Phage therapy is influenced by:

Phage therapy is influenced by:

Country :
the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: a lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Chronolability
Mutation rate
Phenotypical delay
Phage cocktail
My point of view

From Wikipedia


If the target host* of a phage therapy treatment is not
an animal the term "
biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".

"In silico"

From:"Genomics,Proteomics and Clinical Bacteriology", N.Woodford and Alan P.Johnson

Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.

Tuesday, 12 August 2014

Considerations about Mycobacteriophage D29 that can be used potentially in Buruly therapy

I consider  Mycobacteriophage D29 as point of reference and by the information below  I will start again in the analysis of these mycobacteriophages: D29, L5,TM4,BXZ2 and DS6A (specific only for Mycobacterium tuberculosis complex).



1-D29  is capable to lyse and  to grow on Mycobacterium ulcerans



2- D29  is a L5likevirus,where the potential receptors are located in the tail fibers




 3-D29 is a good model for the question regarding the type of receptor and the differences among the receptors because it is a lytic phage that infects both fast and slow- growing  mycobaterial species

 4- DS6A  is capable to lyse and to grow only on  mycobacteria belonging to Mycobacterium tuberculosis complex  and this property give me the possibility to analyse the differences with D29.

 DS6A phage (my old idea




 From this scientific work:



From this scientific work :
" In 1981 Sula et al. reported positive indicators with a reduction in the observed lesions in the spleen, lungs and livers of guinea pigs following therapy with DS6A. More recent work demonstrated that phage therapy could have a beneficial effect in guinea pigs with disseminated tuberculosis, but that its action was considerably less pronounced than that of isoniazid monotherapy."










From this scientific work:
"Sula et al. [63] infected guinea pigs with M. tuberculosis and then treated them with subcutaneous injections of three different bacteriophages twice weekly for 10 weeks.
One of these bacteriophages, designated DS6A, produced an antibacterial effect at least as good as isoniazid."




From this scientific work:
"In addition, the previously isolated phage DS6A, the only one of the 138 phages that does not infect M. smegmatis was sequenced and annotated."